

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 3)\*

**Xilio Therapeutics, Inc.**

---

(Name of Issuer)

**Common Stock, par value \$0.0001 per share**

---

(Title of Class of Securities)

**98422T100**

---

(CUSIP Number)

**12/31/2025**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No. 98422T100

Names of Reporting Persons

1

GILEAD SCIENCES, INC.

Check the appropriate box if a member of a Group (see instructions)

2

- (a)  
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power	
5		
	14,517,678.00	
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power	
6		
	0.00	
	Sole Dispositive Power	
7		
	14,517,678.00	
	Shared Dispositive Power	
8		
	0.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	14,517,678.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	<input type="checkbox"/>	
11	Percent of class represented by amount in row (9)	
	19.9 %	
12	Type of Reporting Person (See Instructions)	
	CO	

**Comment for Type of Reporting Person:** Items 5, 7, 9: Consists of (A) 6,860,223 shares of common stock, par value \$0.0001 per share (the "Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") issued to the Reporting Person on March 28, 2024, (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024, (C) 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024, and (D) 5,412,227 shares of Common Stock issuable upon exercise of pre-funded warrants to purchase Common Stock held by the Reporting Person. Item 11: Based on 67,540,930 shares of Common Stock issued and outstanding as of January 13, 2026, as disclosed in the definitive proxy statement on Schedule 14A filed by the Issuer with the Securities and Exchange Commission (the "SEC") on January 26, 2026.

## SCHEDULE 13G

### Item 1.

Name of issuer:

(a)

Xilio Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

828 Winter Street, Suite 300, Waltham, Massachusetts, 02451

### Item 2.

Name of person filing:

(a)

Gilead Sciences, Inc.

Address or principal business office or, if none, residence:

(b)

333 Lakeside Drive Foster City, California 94404

Citizenship:

(c)

Delaware

Title of class of securities:

(d)

Common Stock, par value \$0.0001 per share

CUSIP No.:

(e)

98422T100

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) 14,517,678

Percent of class:

(b) 19.9 %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

14,517,678

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

14,517,678

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GILEAD SCIENCES, INC.

Signature: /s/ Andrew D. Dickinson

Name/Title: Executive Vice President and Chief Financial  
Officer

Date: 02/12/2026